Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
26. lappuse
... batch of digoxin tablets manufac- tured after January 22 , 1974 , the manu- facturer shall : ( i ) Test a sample of the batch to as- sure that the batch meets all of the re- quirements of The United States Phar- macopeia ( USP XVIII ) ...
... batch of digoxin tablets manufac- tured after January 22 , 1974 , the manu- facturer shall : ( i ) Test a sample of the batch to as- sure that the batch meets all of the re- quirements of The United States Phar- macopeia ( USP XVIII ) ...
203. lappuse
... batch testing by the Food and Drug Administration is nec- essary to assure that all batches of the same drug product ... batch to the Food and Drug Administration and to withhold distribution of the batch until notified by the Food and ...
... batch testing by the Food and Drug Administration is nec- essary to assure that all batches of the same drug product ... batch to the Food and Drug Administration and to withhold distribution of the batch until notified by the Food and ...
300. lappuse
... batch mark means an identifying mark or other identifying device assigned to a batch by the man- ufacturer thereof . [ 39 FR 11750 , Mar. 29 , 1974 , as amended at 39 FR 40285 , Nov. 15 , 1974 ] Subpart B - Packaging and Labeling ...
... batch mark means an identifying mark or other identifying device assigned to a batch by the man- ufacturer thereof . [ 39 FR 11750 , Mar. 29 , 1974 , as amended at 39 FR 40285 , Nov. 15 , 1974 ] Subpart B - Packaging and Labeling ...
304. lappuse
... batch is to be addressed to the Food and Drug Administration , Division of Research and Testing ( HFD - 470 ) , 200 C St. SW . , Washington , DC 20204 . ( b ) The initial request for certifi- cation submitted by any person shall be ...
... batch is to be addressed to the Food and Drug Administration , Division of Research and Testing ( HFD - 470 ) , 200 C St. SW . , Washington , DC 20204 . ( b ) The initial request for certifi- cation submitted by any person shall be ...
305. lappuse
... batch ; in a quantity containing approximately 10,000 U.S.P. units of insulin . ( 4 ) If the batch is to be protamine zinc insulin suspension or isophane in- sulin suspension , the lot of protamine used as an ingredient of the trial mix ...
... batch ; in a quantity containing approximately 10,000 U.S.P. units of insulin . ( 4 ) If the batch is to be protamine zinc insulin suspension or isophane in- sulin suspension , the lot of protamine used as an ingredient of the trial mix ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning